M&A – Talk Bio

Are the Good Times in Biotech Back? – Insights from Post-Hoc Live’s 2025 Industry Sentiment

1 week ago talkbio0Tagged Aggressive Periodontitis, delays, executive survey, Funding, Industry, M&A, Post-Hoc Live, public biotech, Sentiment, United States Food and Drug Administration

biotech sentiment; Post-Hoc Live; 2025 industry outlook; biotech M&A; FDA delays; executive survey; public biotech companies; JP Morgan effect; biotech funding

Biopharma Deal Activity Shows Uptick in Q3 2025: Signs of Recovery and Emerging Trends

2 weeks ago talkbio0Tagged assets, Biopharma, China, Early-stage, Europe, Licensing, M&A, Merus, Metsera, Physical activity, Q3, therapeutic diversification, U.S., Verona Pharma

biopharma; Q3 2025; deal activity; M&A; licensing; therapeutic diversification; early-stage assets; China; US; Europe; Metsera; Verona Pharma; Merus; high-value deals

Pfizer’s $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market

1 month ago talkbio0Tagged biotech acquisition, Glucagon-Like Peptide 1, late-stage clinical development, M&A, Metsera, Obesity, Pfizer, Pharma, pharmaceutical market, Weight Loss

Pfizer; Metsera; obesity drugs; weight loss; pharma M&A; GLP-1; biotech acquisition; pharmaceutical market; late-stage clinical development

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

3 months ago talkbio0Tagged Arenaria, Biological Factors, Biological Science Disciplines, biopharma financing, Conditional, HilleVax, Investments, LAVA, M&A, mezigitamab, OrbiMed, royalty acquisition, XOMA Royalty

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment